<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03094715</url>
  </required_header>
  <id_info>
    <org_study_id>TENSION</org_study_id>
    <nct_id>NCT03094715</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety of Thrombectomy in Stroke With Extended Lesion and Extended Time Window</brief_title>
  <acronym>Tension</acronym>
  <official_title>Efficacy and Safety of Thrombectomy in Stroke With Extended Lesion and Extended Time Window: a Randomized, Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital Heidelberg</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Karolinska University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Eppdata Hamburg, Germany</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Aarhus University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Medical University Innsbruck</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Groupe Hospitalier Pitie-Salpetriere</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Oslo University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University Hospital, Martin</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Charles University, Czech Republic</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Hospices Civils de Lyon</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>CHU de Reims</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Epidemiological and Clinical Research Information Network</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>STROKE ALLIANCE FOR EUROPE</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>INTERNATIONAL CONSORTIUM FOR HEALTHOUTCOMES MEASUREMENT INC.</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Europan Society for Minimally Invasive Neurological Therapy</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Universitätsklinikum Hamburg-Eppendorf</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University Hospital Heidelberg</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_unapproved_device>No</is_unapproved_device>
    <is_ppsd>No</is_ppsd>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      TENSION (Efficacy and safety of ThrombEctomy iN Stroke with extended leSION and extended time
      window) is a prospective, open label, blinded endpoint (PROBE), European two-arm, randomized,
      controlled, post-market study to compare the safety and effectiveness of endovascular
      thrombectomy as compared to best medical care alone in the treatment of acute ischemic stroke
      patients with extended stroke lesions defined by an Alberta Stroke Program Early CT Score
      (ASPECTS) score of 3-5 and in an extended time window (up to 12 hours or unknown time of
      symptom onset). Up to 714 subjects will be randomized. Primary endpoint will be functional
      outcome assessed by the modified Rankin scale at 90 days post-stroke (&quot;mRS shift analysis&quot;).
      By this, TENSION will provide evidence of efficacy and safety of thrombectomy in an acute
      stroke population with uncertain benefit of endovascular stroke treatment.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study is a prospective, open label, blinded endpoint (PROBE),European, two-arm,
      randomized, controlled, post-market study to compare the safety and effectiveness of
      endovascular thrombectomy as compared to best medical care alone in the treatment of acute
      ischemic stroke (AIS) in patients with extended stroke lesions defined by an ASPECT score of
      3-5 and in an extended time window (up to 12 hours, or unknown time of symptom onset). This
      is an adaptive design study, with prospectively stated interim analyses with specified
      stopping rules allowing for the possibility early termination based on either a determination
      of study success or futility.

      Up to 714 subjects will be enrolled in the study and randomized for the Intention to treat
      analysis set. The randomization will be stratified by time from symptom onset (0-6h and
      6-11h/wake up stroke), and stroke severity (NIHSS ≤18, NIHSS &gt;18).

      Interim data analysis is planned after the primary endpoint has been obtained for one third
      and two thirds of the patients. At each of these sample sizes, the available 90-day mRS data
      for each treatment arm will be evaluated. Safety interim analysis will be performed after one
      third and two thirds of the patients have been included.

      Subjects who meet the inclusion criteria will be randomized in a 1:1 ratio to one of the
      following two treatment arms:

      Arm 1: best medical care Arm 2: endovascular thrombectomy and best medical care The primary
      objective of this study is to test efficacy and safety of thrombectomy in acute stroke
      patients with uncertain benefit of endovascular stroke treatment, i.e. extended ischemic
      lesion size with an ASPECT score of 3-5 or late (up to 12 hours) or unknown time window as
      compared to best medical care alone.

      Approximately 40 sites in Up to 20 sites in 8-10 European countries Patients presenting with
      acute ischemic stroke (AIS) based on focal occlusion in the M1 segment of the middle cerebral
      artery (MCA), and/or the intracranial segment of the distal internal carotid artery (ICA),
      determined by Magnetic Resonance Angiography (MRA) or Computed Tomographic Angiography (CTA),
      and who meet all eligibility criteria will be considered for study enrollment.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">June 1, 2018</start_date>
  <completion_date type="Anticipated">September 30, 2022</completion_date>
  <primary_completion_date type="Anticipated">August 31, 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>prospective, open label, blinded endpoint (PROBE), European, two-arm, randomized, controlled, post-market study</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Clinical outcome-modified Rankin Scale at 90 days</measure>
    <time_frame>90 days</time_frame>
    <description>The primary endpoint of the trial is the modified Rankin Scale (mRS) outcome at 90 days post-stroke. The primary effectiveness endpoint analysis is a chi-square test of the difference in linear trends in ordinal mRS outcomes at 90 days post-procedure between treatment groups (&quot;mRS shift analysis&quot;).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Independence - modified Rankin Scale≤2 at 90 days</measure>
    <time_frame>90 days</time_frame>
    <description>Independent neurological outcomes with 90-day mRS≤2</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Moderate Outcome - modified Rankin Scale≤3 at 90 days</measure>
    <time_frame>90 days</time_frame>
    <description>Moderate neurological outcome with 90-day mRS≤3</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Infarct volume 24 hours post procedure</measure>
    <time_frame>18-36 hours</time_frame>
    <description>Infarct volume at 24 hours on post-procedure imaging</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Infarct growth</measure>
    <time_frame>18-36 hours</time_frame>
    <description>Difference of infarct volume from infarct volume as predicted by pre-treatment imaging</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Functional neurological outcome at 12 months - modified Rankin Scale</measure>
    <time_frame>12 month</time_frame>
    <description>Functional neurological outcome at 12 months (±14 days) after stroke (simplified modified Rankin Scale questionnaire, smRSq)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life - PROMIS-10 and EQ-5D</measure>
    <time_frame>90 days - 12 month</time_frame>
    <description>Patient-reported functional health status and quality of life 90 (±14) days and 12 months (±14 days) after stroke (PROMIS-10, EQ-5D)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Post-stroke depression - PHQ-4</measure>
    <time_frame>90 days - 12 month</time_frame>
    <description>Post-stroke depression 90 (±14) days and 12 months (±14 days) after stroke (PHQ-4)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Parenchymal hemorrhage type 2</measure>
    <time_frame>90 days</time_frame>
    <description>blood clots in &gt;30% of the infarcted area with a substantial space-occupying effect.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>modified Rankin Scale between 4-6</measure>
    <time_frame>12 month</time_frame>
    <description>Death or dependency</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Frequencies of Adverse Events (AE) in both treatment arms within the first 7 days</measure>
    <time_frame>12 month</time_frame>
    <description>Serious AEs (SAEs), overall (all-cause mortality) and stroke-related death (i.e., related to intracranial bleeding, midline shift, brain herniation, progression of stroke symptoms, or systemic complications from stroke such as pneumonia).
Space-occupying infarction (malignant brain edema)
New ischemic stroke</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Frequencies of Adverse Events (AE) in both treatment arms within the first 7 days</measure>
    <time_frame>7 days</time_frame>
    <description>Serious AEs (SAEs), overall (all-cause mortality) and stroke-related death (i.e., related to intracranial bleeding, midline shift, brain herniation, progression of stroke symptoms, or systemic complications from stroke such as pneumonia).
Space-occupying infarction (malignant brain edema)
New ischemic stroke</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serious AEs</measure>
    <time_frame>12 month</time_frame>
    <description>Serious AEs (SAEs), overall (all-cause mortality) and stroke-related death (i.e., related to intracranial bleeding, midline shift, brain herniation, progression of stroke symptoms, or systemic complications from stroke such as pneumonia).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Space-occupying infarction</measure>
    <time_frame>18-36 hours</time_frame>
    <description>Malignant brain edema after treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>New ischemic stroke</measure>
    <time_frame>12 month</time_frame>
    <description>New AIS after treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Symptomatic intracranial hemorrhage (sICH) at 24 (18-36) hours (CT or MRI)</measure>
    <time_frame>18-36 hours</time_frame>
    <description>sICH as defined in Safe Implementation of Treatments in Stroke-Monitoring Study (SITS-MOST)
parenchymal hemorrhage type 2 (PH-2)
Frequencies of Adverse Events (AE) in both treatment arms within the first 7 days after treatment
Serious AEs (SAEs), overall (all-cause mortality) and stroke-related death (i.e., related to intracranial bleeding, midline shift, brain herniation, progression of stroke symptoms, or systemic complications from stroke such as pneumonia).
Space-occupying infarction (malignant brain edema)
New ischemic stroke</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cost Utility Assessment</measure>
    <time_frame>12 month</time_frame>
    <description>• Assessment of costs from the time of randomization to the 12-months follow-up, including costs of hospitalization, institutionalized living, outpatient care, informal care provided by relatives and cost of lost productivity</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of Life</measure>
    <time_frame>12 month</time_frame>
    <description>Health related quality of life assessment at 90 (±14) days and 12 months (±14 days)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">714</enrollment>
  <condition>Stroke, Acute</condition>
  <condition>Cerebral Stroke</condition>
  <condition>Cerebrovascular Stroke</condition>
  <condition>Apoplexy; Brain</condition>
  <arm_group>
    <arm_group_label>Thrombectomy</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Endovascular thrombectomy and best medical care</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Best medical care</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Best medical treatment</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Thrombectomy</intervention_name>
    <description>Mechanical thrombectomy with state of the art thrombectomy devices (i.e. stent-retrievers, aspiration catheters). Devices will be used per instructions for use (IFU).</description>
    <arm_group_label>Thrombectomy</arm_group_label>
    <other_name>Mechanical thrombectomy</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Best medical care</intervention_name>
    <description>Best medical treatment will be performed as detailed in established Standard Operating Procedures, following regional guidelines (American Heart Association (AHA), European Stroke Organisation (ESO), Deutsche Schlaganfall-Gesellschaft (DSG), local country, etc.). If applicable, the reason for iv tissue plasminogen activator (tPA) ineligibility has to be documented on the eCRF.</description>
    <arm_group_label>Best medical care</arm_group_label>
    <other_name>Control group</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Randomization within 11 hours after stroke onset (if known) or last seen well.

          -  Endovascular treatment is expected to be finished within 12 hours after known symptom
             onset or last seen well by judgment of the interventional neuroradiologist in charge
             (if stroke onset is known).

          -  Patient must demonstrate clinical signs and symptoms attributable to target area of
             occlusion consistent with the diagnosis of ischemic stroke, including impairment of
             the following: language, motor function, sensation, cognition, gaze, and/or vision for
             at least 30 minutes without relevant improvement.

          -  Female and male patient above 18 up to 80 years of age

          -  NIHSS Score of &lt;26

          -  Signed informed consent (IC) form by patient or legal guardian, or inclusion of
             patient's presumptive will by investigator under emergency situation, but after
             consultation of an independent physician who is familiar with thisthese types of
             illness if the other options are not possible according to local approval.

          -  Prior to new focal neurological deficit, mRS score was ≤2.

        Imaging Inclusion Criteria

          -  A new focal occlusion confirmed by imaging (MRA/CTA) to be accessible to the
             thrombectomy device, and located in the M1 of the middle cerebral artery (MCA) and/or
             the intracranial segment of the distal internal carotid artery (ICA).

          -  CT (non-contrast CT) or DWI with an ASPECT score of 3-5

        Clinical exclusion criteria

          -  Patient is an active participant in another drug or device treatment trial for any
             disease state or patient is expected to start participation in another drug or device
             treatment trial while enrolled in this protocol, unless approved by Sponsor.

          -  Patient has pre-existing neurological or psychiatric disease that could impede the
             study results or would confound the neurological or functional evaluations.

          -  Patient has vascular disease preventing endovascular treatment (e.g. aortic dissection
             or aneurysm, no arterial transfemoral access)

          -  Patient has history of contraindication for contrast medium.

          -  Patient is known to have infective endocarditis

          -  Patient's anticipated life expectancy is less than 6 Months12 months

        Imaging exclusion criteria

          -  ExtracaranialExtracranial CT scanor MR angiography showing high grade stenosis
             expected to require acute stent placement (especially e.g. ICAACI stenting) during the
             procedure to get access to the occlusion

          -  CT or MRI with evidence of: Mass mass effect or intracranial tumor, or hypodensity on
             unenhanced CT and

          -  If CT perfusion is done per institutional standard: CBV drop on CBV maps on CTP, or,
             alternatively as with an ASPECT score of 0-2

          -  If DWI is done per institutional standard,: restricted diffusion on DWI with an ASPECT
             score of 0-2, or above 5
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Götz Thomalla, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Coordination and Project Management Tension, Neurology, UKE Hamburg, Germany</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Martin Bendszus, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Central Trial Management Tension, Neuroradiology, UHHeidelberg, Germany</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Susanne Bonekamp, DVM, PhD</last_name>
    <phone>+49 6221 5635710</phone>
    <email>susanne.bonekamp@med.uni-heidelberg.de</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Lukas Diebold</last_name>
    <phone>+49 6221 5638346</phone>
    <email>lukas.diebold@med.uni-heidleberg.de</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Division of Neuroradiology, Vascular and Interventional Radiology, Department of Radiology, Medical University Graz</name>
      <address>
        <city>Graz</city>
        <zip>8036</zip>
        <country>Austria</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Hannes Deutschmann, Prof. Dr.</last_name>
      <phone>+43(0)31638583271</phone>
      <email>hannes.deutschmann@medunigraz.at</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Medical University Innsbruck</name>
      <address>
        <city>Innsbruck</city>
        <zip>6020</zip>
        <country>Austria</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Elke R Gizewski, Prof. Dr.</last_name>
      <phone>+43 (0)512/504-27095</phone>
      <email>elke.gizewski@i-med.ac.at</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Neuroradiology, Keppler University Hospital Linz</name>
      <address>
        <city>Linz</city>
        <zip>4020</zip>
        <country>Austria</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Johannes Trenkler, Prim. Dr.</last_name>
      <phone>*43 (0)5 7680 87 26701</phone>
      <email>johannes.trenkler@kepleruniklinikum.at</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Department of Neurology, Reseach Institute of Neurointervention, Christian Doppler Clinic, Paracelsus Medical University Salzburg</name>
      <address>
        <city>Salzburg</city>
        <zip>5020</zip>
        <country>Austria</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Monika Killer, Prof. Dr.</last_name>
      <phone>+43(0)664 448356058</phone>
      <email>m.killer@salk.at</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>St. Anne's University Hospital Brno</name>
      <address>
        <city>Brno</city>
        <zip>65691</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Faculty Hospital Hradec Kralove</name>
      <address>
        <city>Hradec Kralove,</city>
        <zip>50005</zip>
        <country>Czechia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Antonin Krajina, MD</last_name>
      <phone>00420602819174</phone>
      <email>antonin.krajina@fnhk.cz</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Comprehensive Stroke Center,Department of Neurology, Palacky University Hospital,</name>
      <address>
        <city>Olomouc</city>
        <zip>77520</zip>
        <country>Czechia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Daniel Šaňák, MD</last_name>
      <phone>00420588442836</phone>
      <email>daniel.sanak@fnol.cz</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Comprehensive stroke center,University Hospital Ostrava</name>
      <address>
        <city>Ostrava</city>
        <zip>70852</zip>
        <country>Czechia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Martin Roubec, MD</last_name>
      <phone>00420597375630</phone>
      <email>martin.roubec@fno.cz</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Military University Hospital Prague</name>
      <address>
        <city>Prague</city>
        <zip>16902</zip>
        <country>Czechia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Martin Šrámek, MD</last_name>
      <phone>00420739323104</phone>
      <email>Martin.Sramek@uvn.cz</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Aalborg University Hospital</name>
      <address>
        <city>Aalborg</city>
        <zip>9000</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Aarhus University Hospital</name>
      <address>
        <city>Aarhus</city>
        <zip>8000</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Claus Z Simonsen, MD</last_name>
      <phone>004550240543</phone>
      <email>clasim@rm.dk</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hôpiteaux Universitaires Paris-Sud, Hôpital Bicêtre</name>
      <address>
        <city>Le Kremlin-Bicêtre</city>
        <zip>94270</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Laurent Spelle, MD</last_name>
      <phone>+33 1 45 21 73 81</phone>
      <email>laurent@spelle.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHU de Nancy</name>
      <address>
        <city>Nancy</city>
        <zip>54035</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Serge Bracard, MD</last_name>
      <email>s.bracard@chu-nancy.fr</email>
    </contact>
    <contact_backup>
      <last_name>Rene Anxionnat, MD</last_name>
      <email>r.anxionnat@chu-nancy.fr</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Hôpital Pitié-Salpêtrière</name>
      <address>
        <city>Paris</city>
        <zip>75013</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Frederic Clarençon, MD, Pr</last_name>
      <email>fredclare5@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Université Reims Champagne Ardenne/ Department of Neuroradiology, Hôpital Maison Blanche</name>
      <address>
        <city>Reims</city>
        <zip>51100</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Laurent Pierot, MD</last_name>
      <phone>0033 3 26 91 30 00</phone>
      <email>lpierot@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHU de Rennes/Centre Urgences-Réanimations</name>
      <address>
        <city>Rennes</city>
        <zip>35033</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Jean-Yves Gauvrit, MD</last_name>
      <phone>'+33 2 99 28 42 61</phone>
      <email>jean-yves.gauvrit@chu-rennes.fr</email>
    </contact>
    <investigator>
      <last_name>Jean-Christophe Ferré, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU de Rouen</name>
      <address>
        <city>Rouen</city>
        <zip>76000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Christophe Papagiannaki, MD</last_name>
      <email>chrisanthi.papa@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHU Saint-Étienne</name>
      <address>
        <city>Saint-Priest-en-Jarez</city>
        <zip>42270</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Mohamed Aggour, MD</last_name>
      <phone>+33 4 77 82 90 28</phone>
      <email>mohamed.aggour@chu-st-etienne.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHRU Hôpiteaux de Tours / Hôpital Bretonneau</name>
      <address>
        <city>Tours</city>
        <zip>37044</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Denis Herbreteau, MD</last_name>
      <phone>'+33 2 47 47 38 65</phone>
      <email>herbreteau@med.univ-tours.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum KK Bochum-Langendreer Institut für Diagnostische und Interventionelle Radiologie, Neuroradiologie und Nuklearmedizin</name>
      <address>
        <city>Bochum</city>
        <zip>44892</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Werner Weber, MS</last_name>
      <phone>0049 (234) 299-3801</phone>
      <email>werner.weber@kk-bochum.de</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Gesundheit Nord gGmbH Klinikverbund Bremen</name>
      <address>
        <city>Bremen</city>
        <zip>28211</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Andreas Kastrup, MD</last_name>
      <phone>0049 4214082523</phone>
      <email>Andreas.Kastrup@klinikum-bremen-ost.de</email>
    </contact>
    <contact_backup>
      <last_name>Halil Merdivan</last_name>
      <phone>+49 (0)421 497</phone>
      <phone_ext>2675</phone_ext>
      <email>halil.merdivan@klinikum-bremen-mitte.de</email>
    </contact_backup>
    <investigator>
      <last_name>Panagiotis Papanagiotou, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Klinik für Radiologie und Neuroradiologie am Klinikum Mitte</name>
      <address>
        <city>Dortmund</city>
        <zip>44137</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Stefan Rhode, MD</last_name>
      <phone>0049231 95318601</phone>
      <email>stefan.rohde@klinikumdo.de</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Carl Gustav Carus Dresden</name>
      <address>
        <city>Dresden</city>
        <zip>01307</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Alfried Krupp Krankenhaus Rüttenscheid</name>
      <address>
        <city>Essen</city>
        <zip>45131</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>René Chapot, MD</last_name>
      <phone>0049201 43441629</phone>
      <email>rene.chapot@krupp-krankenhaus.de</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Hamburg-Eppendorf</name>
      <address>
        <city>Hamburg</city>
        <zip>20251</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Neuroradiologie Universitätsklinikum Heidelberg</name>
      <address>
        <city>Heidelberg</city>
        <zip>69120</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Martin Bendszus, MD</last_name>
      <phone>00496221 567566</phone>
      <email>martin.bendszus@med.uni-heidelberg.de</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Technische Universität München / Klinikum rechts der Isar</name>
      <address>
        <city>München</city>
        <zip>81675</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Claus Zimmer, MD</last_name>
      <phone>+49 89 4140 4651</phone>
      <email>claus.zimmer@tum.de</email>
    </contact>
    <contact_backup>
      <last_name>Christian Maegerlein</last_name>
      <phone>+49 (0)89 4140 - 9699</phone>
      <email>christian.maegerlein@tum.de</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Klinikum Stuttgart - Katharinenhospital (KH)</name>
      <address>
        <city>Stuttgart</city>
        <zip>70174</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Hans Henkes, MD</last_name>
      <phone>0049711 278-01</phone>
      <email>h.henkes@klinikum-stuttgart.de</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Würzburg</name>
      <address>
        <city>Würzburg</city>
        <zip>97080</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Mirko Pham, MD</last_name>
      <phone>004993120134791</phone>
      <email>pham_m@ukw.de</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Oslo University Hospital</name>
      <address>
        <city>Oslo</city>
        <zip>NO-0407</zip>
        <country>Norway</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Eivind Berge, MD</last_name>
      <phone>(+47) 22119100</phone>
      <email>eivind.berge@medisin.uio.no</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Comenius University's Jessenius Faculty of Medicine and University Hospital</name>
      <address>
        <city>Martin</city>
        <zip>03659</zip>
        <country>Slovakia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>K Zelenak, MD</last_name>
      <phone>+ 421 904 164 847</phone>
      <email>zelenak@jfmed.uniba.sk</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Faculty Hospital Nitra</name>
      <address>
        <city>Nitra</city>
        <zip>95001</zip>
        <country>Slovakia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>M Brozman, MD</last_name>
      <phone>+ 421 37 6545 530</phone>
      <email>brozman@fnnitra.sk</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Faculty Hospital Trnava</name>
      <address>
        <city>Trnava</city>
        <zip>91775</zip>
        <country>Slovakia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>G Krastev, MD</last_name>
      <phone>+ 421 33 5938 450</phone>
      <email>krnstevg@stonline.sk</email>
    </contact>
    <contact_backup>
      <last_name>Andrej Klepanec, MD</last_name>
      <email>andrej.klepanec@fntt.sk</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Sahlgrenska Sjukhuset</name>
      <address>
        <city>Göteborg</city>
        <zip>41345</zip>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Alexandros Rentzos, MD</last_name>
      <phone>+46313421000</phone>
      <email>alexandros.rentzos@vgregion.se</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Karolinska Institutet</name>
      <address>
        <city>Stockholm</city>
        <zip>17176</zip>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Patrick A Brouwer, MD</last_name>
      <email>patrickbrouwermd@gmail.com</email>
    </contact>
  </location>
  <location_countries>
    <country>Austria</country>
    <country>Czechia</country>
    <country>Denmark</country>
    <country>France</country>
    <country>Germany</country>
    <country>Norway</country>
    <country>Slovakia</country>
    <country>Sweden</country>
  </location_countries>
  <verification_date>March 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 16, 2017</study_first_submitted>
  <study_first_submitted_qc>March 22, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">March 29, 2017</study_first_posted>
  <last_update_submitted>March 22, 2018</last_update_submitted>
  <last_update_submitted_qc>March 22, 2018</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 26, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University Hospital Heidelberg</investigator_affiliation>
    <investigator_full_name>Martin Bendszus</investigator_full_name>
    <investigator_title>Central trial management, Coordinating investigator</investigator_title>
  </responsible_party>
  <keyword>Mechanical thrombectomy</keyword>
  <keyword>Endovascular thrombectomy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Stroke</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

